AusperBio secures funds to advance AHB-137 for CHB

AusperBio has successfully raised $37 million in a Series A financing round to advance the clinical development of their innovative therapy, AHB-137, aimed at treating chronic hepatitis B (CHB). This significant funding effort was led by its ongoing investor, the InnoPinnacle Fund, and included new investors such as Qiming Venture Partners, Yuanbio Venture Capital, Hankang Capital, and Genesis Capital.

The newly secured funds will play a crucial role in progressing the clinical trials of AHB-137, while also bolstering AusperBio’s Med-Oligo technology platform and expanding its pipeline of products. This platform is central to the company's mission of enhancing antisense oligonucleotide (ASO) therapeutics for various disease categories, including viral infections, metabolic diseases, genetic disorders, and immune-related conditions.

AHB-137 is a groundbreaking therapy derived from AusperBio’s Med-Oligo technology. It is an unconjugated ASO therapy specifically engineered to target chronic hepatitis B, aiming for a functional cure. The therapy is currently undergoing a Phase Ib trial in multiple international locations and a Phase II trial in China. This dual-phase approach highlights the company's aggressive strategy to bring this potential treatment to market swiftly.

The significance of this development was underscored when AusperBio received breakthrough therapy designation in China for AHB-137. This designation is intended to accelerate the development and review processes, demonstrating the urgency and potential impact of this therapy.

AusperBio’s co-founder and CEO, Dr. Guofeng Cheng, expressed his enthusiasm about the successful financing round, which marks a pivotal milestone in the company's journey. He stated, "This financing round represents a significant milestone that recognizes our scientific and clinical achievements to date. The shared commitment from our investors to developing new therapeutics for CHB patients is truly inspiring."

Dr. Cheng further emphasized the importance of the breakthrough therapy designation from China’s Centre for Drug Evaluation (CDE), which, combined with the new funding, positions the company to rapidly advance the clinical development of AHB-137. He highlighted the goal of moving closer to providing a crucial new treatment option for patients suffering from chronic hepatitis B.

The Med-Oligo ASO platform developed by AusperBio employs targeted delivery conjugation technologies, offering a modular approach that could transform treatment possibilities across a wide range of diseases. This innovative platform is expected to make significant contributions to the company's pipeline and its broader therapeutic strategy.

AusperBio’s global development strategy is meticulously crafted to expedite the advancement of AHB-137 as a potential cure for chronic hepatitis B. The company’s approach reflects a blend of scientific innovation and strategic investment aimed at addressing a critical unmet medical need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!